From: Innovative method of alopecia treatment by autologous adipose-derived SVF
Inclusion | Men or women with AGA symptoms |
Healthy subjects aged 43–64 years who provide written consent suitable to this study | |
Subjects with grades II–VI Norwood–Hamilton or Class I–III Ludwig | |
Subjects with severe hair loss within past 12 months | |
Subjects who do not have any specific diseases or abnormal health conditions in the interview in relation to AGA | |
Subjects with required proper hypodermic fat from the abdominal or thigh without any problem in the process of liposuction | |
Women who are not pregnant during the test period | |
Exclusion | Subjects with prescription for inflammation, infection, malignancy, allergic diseases, autoimmune diseases, pregnancy, diabetes, anti-thrombotic drugs, etc. |
Subjects who do not experience any improvement previously in the hair loss treatments, or who have sensitive skin and suffer from the skin irritation and scratch on the surface of scalp during treatments | |
Subjects with psychiatric history or other physical illness within 30 days of this clinical trials | |
Subjects with a history of abnormalities in the blood vessels, heart, lungs, kidneys, digestive organs, liver, central nervous systems, etc., or who may have a risk of developing these diseases | |
Women who are during pregnancy or plan on being pregnant throughout the study |